BJMO - volume 12, issue 4, august 2018
Prof B. Neyns MD, PhD, G. Awada MD, J. K. Schwarze
This article will summarize the key data in the field of immunotherapy presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
Read more
BJMO - volume 11, issue 9, february 2017
Prof B. Neyns MD, PhD, G. Awada MD, A. Rogiers MD
Over the past 10 years, several effective new therapies have been developed for patients with advanced melanoma. Since 2010, the primary endpoint of every major phase III trial in this setting has been met, revolutionizing the treatment options and survival for patients with unresectable advanced melanoma. With increasing numbers of patients experiencing durable remissions with these agents, even without continuing therapy, the issue of melanoma survival care becomes of relevance to more patients than ever before.
Read more
Top
